Presurgical systemic treatment of nonmetastatic breast cancer: Facts and open questions

Oncologist

Volumn 13, Issue 11, 2008, Pages 1137-1148

  Berruti, Alfredo ^a   Brizzi, Maria Pia ^a   Generali, Daniele ^b   Ardine, Mara ^c   Dogliotti, Luigi ^a   Bruzzi, Paolo ^d   Bottini, Alberto ^b  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c Ospedale di Carmagnola   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; Pathological complete response; Primary systemic treatment; Surrogacy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; GEFITINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SENSITIVITY; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIMARY SYSTEMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 56749169261     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0162     Document Type: Review

References (77)

1. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;3:82:1539-1545.
2. Sachelarie I, Grossbard ML, Chadha M et al. Primary systemic therapy of breast cancer. The Oncologist 2006;11:574-589.
3. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
4. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005;97:188-194.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Goldhirsch A, Glick JH, Gelber RD et al.; Panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
7. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9:183-195.
8. Aapro MS. Neoadjuvant therapy in breast cancer: Can we define its role? The Oncologist 2001;6(suppl 3):36-39.
9. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-3417.
10. Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. J Clin Oncol 2002;21:34a.
11. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-850.
12. Baldini E, Gardin G, Giannessi PG et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: A randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003;14:227-232.
13. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003;21:4165-4174.
14. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785.
15. Kuemmel S, Krocker J, Kohls A et al. A phase III randomised trial comparing the tolerability of dose-dense chemotherapy in older to that in younger breast cancer patients with four or more positive lymph nodes. J Clin Oncol 2004;22(14 suppl):589.
16. Smith IE, A'Hern RP, Coombes GA et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15:751-758.
17. Dieras V, Fumoleau P, Romieu G et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-4965.
18. Ditsch N, Bauerfeind I, Kahlert St et al. Prospective randomized comparison of neoadjuvant /primary systemic therapy (PST) with dose-dense sequential epirubicin (E)/ paclitaxel (P) chemotherapy versus standard dose therapy regimen in patients with breast cancer (bc), multicentre study of the AGO, Germany): Subgroup analysis of inflammatory bc. Breast Cancer Res Treat 2005;94(suppl 1):223s.
19. Lee KS, Lee ES, Kwon YM et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/ cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC). Breast Cancer Res Treat 2005;94(suppl 1):224s.
20. Chua S, Smith IE, A'Hern RP et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: Analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol 2005;16:1435-1441.
21. Cocconi G, Di Blasio B, Boni C et al. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: Short-term responses translated into long-term outcomes. Ann Oncol 2005;16:1469-1476.
22. Evans TRJ, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988-2995.
23. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.
24. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
25. Ellis GK, Green SJ, Russell CA et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(18 suppl):12s.
26. Roché H, Penault-Llorca F, Berton Rigaud D et al. Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine + epirubicin + cyclophosphamide vs 5FU + epirubicin + cyclophosphamide in operable breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):212s.
27. Ejlertsen B, Bentzon N, Jacobsen E et al. Randomized placebo-controlled phase II trial with preoperative epirubicin and cyclophosphamide +/- gefitinib in patients with operable and estrogen receptor negative breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):214s.
28. Müller C, Caputo A, Schumacher M et al. Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: Further results from a randomised controlled trial. Eur J Cancer 2007;43:1654-1661.
29. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995;180:297-306.
30. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 2003;12:320-327.
31. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
32. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
33. Scholl SM, Pierga JY, Asselain B et al. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995;31A:1969-1975.
34. Sinn HP, Schmid H, Junkermann H et al. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy.] Geburtshilfe Frauenheilkd 1994;54:552-558. In German.
35. Honkoop AH, van Diest PJ, de Jong JS et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-626.
36. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228.
37. Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer 2006;13:254-259.
38. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
39. Mazouni C, Peintinger F, Wan-Kau S et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650-2655.
40. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-1949.
41. Bottini A, Berruti A, Brizzi MP et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: A single-institution phase III trial. Endocr Relat Cancer 2005;12:383-392.
42. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628.
43. Gianni L, Baselga J, Eiermann W et al.; European Cooperative Trial in Operable Breast Cancer Study Group. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715-8721.
44. Jones RL, Lakhani SR, Ring AE et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006;94:358-362.
45. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
46. Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(suppl 2):S69-S74.
47. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
48. Roché H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664-5671.
49. Martin M, Rodriguez-Lescure A, Ruiz A et al. Randomized phase 3 trial of Fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805-814.
50. Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073-1079.
51. Eiermann W, Pienkowski T, Crown J et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin cyclophosphamide followed by docetaxel (AC-T) in HER2-negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005:94:S62.
52. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 2005;23:3676-3685.
53. Lybaert W, Wildiers H, Neven P et al. Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients with locally advanced breast cancer (LABC): Preliminary safety and efficacy data. Breast Cancer Res Treat 2006;100(suppl 1):232s.
54. Sikov WM, Fenton MA, Strenger R et al. Preliminary recurrence and survival analysis of patients receiving neoadjuvant q4week carboplatin and weekly paclitaxel +/- weekly trastuzumab in resectable and locally advanced breast cancer: Update of BrUOG BR-95. Breast Cancer Res Treat 2007;106(suppl 1):227s.
55. Tripathy D, Moisa C, Gluck S et al. Neoadjuvant capecitabine plus docetaxel +/- trastuzumab therapy for recently diagnosed breast cancer: Phase II results. Breast Cancer Res Treat 2007;106(suppl 1):201s.
56. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
57. von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005;16:56-63.
58. von Minckwitz G, Kümmel S, Vogel P et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-551.
59. Smith IE, Dowsett M, Ebbs SR et al.; IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
60. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006;106:2095-2103.
61. Howell A, Cuzick J, Baum M et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
62. Eiermann W, Paepke S, Appfelstaedt J et al.; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
63. Thurlimann B, Keshaviah A, Coates AS et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
64. Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [abstract]. J Clin Oncol 2005;23(16 suppl):530.
65. Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 2005;23:2477-2492.
66. Molenberghs G, Burzykowski T, Alonso A et al. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 2004;13:177-206.
67. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431-440.
68. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
69. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-378.
70. Bruzzi P, Del Mastro L, Soriani MP et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005;23:5117-5125.
71. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027.
72. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
73. Fiorentino C, Berruti A, Bottini A et al. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 2001;69:143-151.
74. Bodini M, Berruti A, Bottini A et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 2004;85:211-218.
75. Martincich L, Montemurro F, De Rosa G et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
76. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 2006;14:383-389.
77. McDermott GM, Welch A, Staff RT et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75-84.